Bepreve - (1.5% ; Solution/Drops, Opthalmic)

Generic Name	Bepotastine Besilate	Innovator	BAUSCH AND LOMB INC
Dosage	1.5% ; Solution/Drops, Opthalmic	Branded US Sales	Less Than $1000 mn
Probable FTF	Less Than 5	Known Para IV Filers	Less Than 5
Other ANDA developers	Less Than 5	Tentative Approvals	Less Than 5
Final Approvals	Less Than 5	Generic Launches	Less Than 5
Indication	Bepreve™ is a histamine H1 receptor antagonist indicated for the treatment of itching associated with allergic conjunctivitis.
Complexities	Yes

Executive Summary

Patent Status

Launch Timelines and Competition

Company	FTF Status / 180 days exclusivity	30-Months stay	Current Litigation Status	Current Approval Status	Likelihood of launch
******	*** \ *********	*** **, ****	*******	****	****** **** ********
*****	*** \ *********	*** **, ****	*******	****	****** **** ********
******	*** \ *********	*** **, ****	*******	********	********

Chronology Of Events